Free Trial

Nurix Therapeutics (NRIX) Financials

Nurix Therapeutics logo
$10.07 -0.39 (-3.73%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$10.22 +0.15 (+1.48%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Nurix Therapeutics

Annual Income Statements for Nurix Therapeutics

This table shows Nurix Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024
Net Income / (Loss) Attributable to Common Shareholders
-22 -43 -117 -180 -144 -194
Consolidated Net Income / (Loss)
-22 -43 -117 -180 -144 -194
Net Income / (Loss) Continuing Operations
-22 -43 -117 -180 -144 -194
Total Pre-Tax Income
-21 -64 -117 -180 -144 -193
Total Operating Income
-22 -65 -118 -184 -155 -213
Total Gross Profit
31 18 30 39 77 55
Total Revenue
31 18 30 39 77 55
Operating Revenue
31 18 30 39 77 55
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
53 83 148 222 232 268
Selling, General & Admin Expense
8.33 16 31 38 43 46
Research & Development Expense
45 66 116 184 189 222
Total Other Income / (Expense), net
0.78 1.21 0.82 3.51 11 20
Interest & Investment Income
0.78 1.21 0.82 3.51 11 20
Income Tax Expense
0.24 -21 0.13 0.00 0.00 0.27
Basic Earnings per Share
($6.59) ($2.76) ($2.73) ($3.71) ($2.65) ($2.88)
Weighted Average Basic Shares Outstanding
3.29M 15.67M 42.90M 48.61M 54.34M 67.12M
Diluted Earnings per Share
($6.59) ($2.76) ($2.73) ($3.71) ($2.65) ($2.88)
Weighted Average Diluted Shares Outstanding
3.29M 15.67M 42.90M 48.61M 54.34M 67.12M
Weighted Average Basic & Diluted Shares Outstanding
3.29M 15.67M 42.90M 47.27M 48.89M 75.89M
Cash Dividends to Common per Share
$0.00 $0.00 - - - $0.00

Quarterly Income Statements for Nurix Therapeutics

This table shows Nurix Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 11/30/2022 2/28/2023 5/31/2023 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025 5/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-47 -41 -24 -37 -42 -42 -45 -49 -59 -56 -43
Consolidated Net Income / (Loss)
-47 -41 -24 -37 -42 -42 -45 -49 -59 -56 -43
Net Income / (Loss) Continuing Operations
-47 -41 -24 -37 -42 -42 -45 -49 -59 -56 -43
Total Pre-Tax Income
-47 -41 -24 -37 -42 -41 -44 -49 -59 -56 -43
Total Operating Income
-49 -43 -27 -40 -45 -45 -49 -55 -65 -63 -48
Total Gross Profit
6.78 13 31 18 15 17 12 13 13 18 44
Total Revenue
6.78 13 31 18 15 17 12 13 13 18 44
Operating Revenue
6.78 - 31 18 - 17 12 13 - 18 44
Total Cost of Revenue
- 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses
55 56 57 58 60 62 61 67 78 81 92
Selling, General & Admin Expense
9.37 9.82 12 11 11 12 12 12 11 12 14
Research & Development Expense
46 46 46 48 50 50 49 55 67 70 78
Total Other Income / (Expense), net
1.97 2.22 2.49 3.03 3.38 3.79 4.08 5.74 6.12 6.51 5.62
Interest & Investment Income
1.97 2.22 2.49 3.03 3.38 3.79 4.08 5.74 6.12 6.51 5.62
Income Tax Expense
- 0.00 0.00 0.00 - 0.09 0.09 0.08 0.01 0.00 0.76
Basic Earnings per Share
($0.85) ($0.75) ($0.45) ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52)
Weighted Average Basic Shares Outstanding
48.61M 54.03M 54.26M 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M
Diluted Earnings per Share
($0.85) ($0.75) ($0.45) ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52)
Weighted Average Diluted Shares Outstanding
48.61M 54.03M 54.26M 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M
Weighted Average Basic & Diluted Shares Outstanding
47.27M 47.45M 48.20M 48.50M 48.89M 49.15M 64.41M 70.84M 75.89M 76.24M 76.45M

Annual Cash Flow Statements for Nurix Therapeutics

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024
Net Change in Cash & Equivalents
9.23 85 -39 -15 -9.85 55
Net Cash From Operating Activities
0.60 -0.08 -84 -160 -81 -173
Net Cash From Continuing Operating Activities
0.60 -0.08 -84 -160 -81 -173
Net Income / (Loss) Continuing Operations
-22 -43 -117 -180 -144 -194
Consolidated Net Income / (Loss)
-22 -43 -117 -180 -144 -194
Depreciation Expense
2.35 2.18 2.79 5.35 7.53 9.32
Amortization Expense
-0.11 0.27 5.00 5.89 0.70 -4.18
Non-Cash Adjustments To Reconcile Net Income
0.51 -3.20 16 28 34 34
Changes in Operating Assets and Liabilities, net
20 44 9.11 -19 20 -18
Net Cash From Investing Activities
8.50 -254 -108 27 68 -258
Net Cash From Continuing Investing Activities
8.50 -254 -108 27 68 -258
Purchase of Property, Plant & Equipment
-1.65 -4.55 -5.66 -12 -8.40 -9.27
Purchase of Investments
-9.35 -275 -348 -239 -246 -708
Sale and/or Maturity of Investments
20 25 246 279 323 460
Net Cash From Financing Activities
0.13 339 154 117 3.22 486
Net Cash From Continuing Financing Activities
0.13 339 154 117 3.22 486
Repurchase of Preferred Equity
-0.02 - -0.00 0.00 0.00 -0.02
Issuance of Common Equity
0.00 218 152 116 2.23 481
Other Financing Activities, net
0.14 0.97 1.67 1.08 0.99 5.06

Quarterly Cash Flow Statements for Nurix Therapeutics

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 11/30/2022 2/28/2023 5/31/2023 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025 5/31/2025
Net Change in Cash & Equivalents
17 -31 25 -17 12 -4.81 67 -18 11 -34 8.34
Net Cash From Operating Activities
-38 -48 -18 -41 27 -42 -40 -42 -49 -61 -63
Net Cash From Continuing Operating Activities
-38 -48 -18 -41 27 -42 -40 -42 -49 -61 -63
Net Income / (Loss) Continuing Operations
-47 -41 -24 -37 -42 -42 -45 -49 -59 -56 -43
Consolidated Net Income / (Loss)
-47 -41 -24 -37 -42 -42 -45 -49 -59 -56 -43
Depreciation Expense
1.62 1.75 1.90 1.95 1.93 2.05 2.33 2.39 2.55 2.35 2.24
Amortization Expense
0.77 0.61 0.45 -0.21 -0.15 -0.09 -0.40 -1.95 -1.74 -1.78 0.15
Non-Cash Adjustments To Reconcile Net Income
8.30 8.54 8.76 8.89 8.04 7.82 8.85 9.04 8.54 8.72 10
Changes in Operating Assets and Liabilities, net
-1.92 -19 -5.30 -15 59 -10 -5.94 -2.70 0.45 -14 -32
Net Cash From Investing Activities
55 16 44 23 -14 36 -131 -21 -141 26 71
Net Cash From Continuing Investing Activities
55 16 44 23 -14 36 -131 -21 -141 26 71
Purchase of Property, Plant & Equipment
-2.57 -2.28 -1.08 -2.46 -2.59 -2.88 -1.94 -2.35 -2.11 -3.49 -2.68
Purchase of Investments
-27 -23 -61 -75 -88 -55 -225 -130 -298 -110 -68
Sale and/or Maturity of Investments
84 41 106 100 77 93 96 111 160 139 142
Net Cash From Financing Activities
-0.14 1.48 0.03 1.70 0.01 1.62 238 46 201 1.47 0.01
Net Cash From Continuing Financing Activities
-0.14 1.48 0.03 1.70 0.01 1.62 238 46 201 1.47 0.01
Other Financing Activities, net
0.05 0.03 0.03 0.93 0.01 0.36 0.22 3.04 1.45 0.22 0.01

Annual Balance Sheets for Nurix Therapeutics

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024
Total Assets
44 396 477 417 356 669
Total Current Assets
39 298 311 318 296 619
Cash & Equivalents
35 119 81 64 55 110
Short-Term Investments
2.90 162 215 245 233 500
Accounts Receivable
- - 6.00 - - 0.00
Prepaid Expenses
1.63 5.94 9.19 9.31 7.60 9.80
Plant, Property, & Equipment, net
3.87 6.67 11 17 17 18
Total Noncurrent Assets
0.82 91 154 81 43 32
Other Noncurrent Operating Assets
0.32 0.35 17 17 36 32
Total Liabilities & Shareholders' Equity
44 396 477 417 356 669
Total Liabilities
54 106 134 113 155 142
Total Current Liabilities
16 45 66 71 87 96
Accounts Payable
1.60 3.41 6.65 5.06 6.40 11
Accrued Expenses
4.93 - 15 22 25 38
Current Deferred Revenue
9.61 33 41 38 48 38
Other Current Liabilities
- - 3.85 5.53 7.49 8.01
Total Noncurrent Liabilities
37 62 68 42 68 46
Noncurrent Deferred Revenue
36 61 59 36 45 26
Other Noncurrent Operating Liabilities
1.74 0.85 9.19 6.43 23 20
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-58 290 342 304 200 527
Total Preferred & Common Equity
-58 290 342 304 200 527
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-58 290 342 304 200 527
Common Stock
2.74 394 564 709 746 1,266
Retained Earnings
-60 -104 -221 -401 -545 -739
Accumulated Other Comprehensive Income / (Loss)
-0.00 0.09 -0.61 -4.32 -0.66 0.15

Quarterly Balance Sheets for Nurix Therapeutics

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 8/31/2022 2/28/2023 5/31/2023 8/31/2023 2/29/2024 5/31/2024 8/31/2024 2/28/2025 5/31/2025
Total Assets
459 370 351 308 313 511 514 615 592
Total Current Assets
355 288 290 268 251 450 456 564 515
Cash & Equivalents
48 34 59 42 50 117 99 76 84
Short-Term Investments
297 244 222 217 194 326 349 474 402
Accounts Receivable
0.00 - - 2.00 - - - - 19
Prepaid Expenses
10 11 8.84 7.10 6.98 7.08 7.99 14 11
Plant, Property, & Equipment, net
17 18 18 17 18 19 17 18 19
Total Noncurrent Assets
88 64 42 24 44 42 40 33 57
Other Noncurrent Operating Assets
19 16 15 14 34 33 31 33 57
Total Liabilities & Shareholders' Equity
459 370 351 308 313 511 514 615 592
Total Liabilities
117 96 91 74 144 140 137 134 144
Total Current Liabilities
68 65 72 61 88 81 86 90 76
Accounts Payable
6.05 5.63 4.53 2.19 5.92 2.81 3.92 8.40 5.95
Accrued Expenses
20 15 18 22 28 23 28 44 37
Current Deferred Revenue
36 38 44 32 46 47 48 31 27
Other Current Liabilities
5.50 5.56 5.58 5.36 7.31 7.93 6.55 6.64 5.24
Total Noncurrent Liabilities
49 31 18 13 56 60 50 44 68
Noncurrent Deferred Revenue
42 26 15 10 34 39 30 24 22
Other Noncurrent Operating Liabilities
7.75 5.11 3.76 2.64 22 21 21 20 47
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
343 274 260 234 169 371 377 481 448
Total Preferred & Common Equity
343 274 260 234 169 371 377 481 448
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
343 274 260 234 169 371 377 481 448
Common Stock
701 719 728 738 756 1,002 1,057 1,276 1,286
Retained Earnings
-355 -442 -466 -503 -587 -631 -680 -795 -839
Accumulated Other Comprehensive Income / (Loss)
-3.74 -3.25 -1.90 -1.23 -0.35 -0.14 0.34 0.23 -0.02

Annual Metrics And Ratios for Nurix Therapeutics

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 11/30/2019 11/30/2020 11/30/2021 11/30/2022 11/30/2023 11/30/2024
Growth Metrics
- - - - - -
Revenue Growth
0.00% -42.73% 66.95% 29.84% 99.31% -29.15%
EBITDA Growth
0.00% -212.79% -76.07% -56.80% 14.95% -41.58%
EBIT Growth
0.00% -192.24% -81.41% -55.97% 15.67% -37.38%
NOPAT Growth
0.00% -192.24% -81.41% -55.97% 15.67% -37.38%
Net Income Growth
0.00% -99.28% -171.02% -53.90% 20.19% -34.47%
EPS Growth
0.00% 58.12% 1.09% -35.90% 28.57% -8.68%
Operating Cash Flow Growth
0.00% -113.31% -105,356.25% -89.42% 49.09% -112.11%
Free Cash Flow Firm Growth
0.00% 0.00% -230.20% -129.50% 44.64% -94.34%
Invested Capital Growth
0.00% -53.82% -23.37% 23.49% -36.80% 12.91%
Revenue Q/Q Growth
0.00% 0.00% 2.43% -1.56% 12.21% -3.32%
EBITDA Q/Q Growth
0.00% 0.00% -17.65% -6.52% 1.84% -10.82%
EBIT Q/Q Growth
0.00% 0.00% -17.96% -6.20% 2.12% -9.98%
NOPAT Q/Q Growth
0.00% 0.00% -17.96% -6.20% 2.12% -9.98%
Net Income Q/Q Growth
0.00% 0.00% -17.89% -5.26% 3.20% -9.38%
EPS Q/Q Growth
0.00% 0.00% -5,360.00% 0.00% 2.93% 1.03%
Operating Cash Flow Q/Q Growth
0.00% -101.05% -14.11% -4.61% 44.27% -77.66%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -6.91% 43.53% -79.61%
Invested Capital Q/Q Growth
0.00% 0.00% -0.49% 2.44% -171.60% -2.38%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-64.25% -350.90% -370.08% -446.92% -190.72% -381.10%
Operating Margin
-71.46% -364.66% -396.26% -476.01% -201.41% -390.52%
EBIT Margin
-71.46% -364.66% -396.26% -476.01% -201.41% -390.52%
Profit (Net Income) Margin
-69.74% -242.66% -393.93% -466.93% -186.98% -354.85%
Tax Burden Percent
101.11% 67.80% 100.11% 100.00% 100.00% 100.14%
Interest Burden Percent
96.51% 98.14% 99.30% 98.09% 92.83% 90.74%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
227.95% -30.80% -37.05% -55.84% -57.10% -53.22%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-50.48% -29.51% -27.00% -41.16% -40.15% -41.57%
Return on Assets (ROA)
-49.26% -19.64% -26.85% -40.37% -37.28% -37.77%
Return on Common Equity (ROCE)
1,382.10% -25.52% -37.05% -55.84% -57.10% -53.22%
Return on Equity Simple (ROE_SIMPLE)
37.60% -14.90% -34.24% -59.39% -71.80% -36.73%
Net Operating Profit after Tax (NOPAT)
-16 -45 -83 -129 -109 -149
NOPAT Margin
-50.02% -255.26% -277.38% -333.20% -140.99% -273.37%
Net Nonoperating Expense Percent (NNEP)
-16.05% 1.12% -8.71% -12.82% -10.59% -9.82%
Return On Investment Capital (ROIC_SIMPLE)
- - - -42.38% -54.14% -28.30%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
26.76% 91.52% 104.88% 98.37% 55.73% 84.23%
R&D to Revenue
144.71% 373.14% 391.37% 477.64% 245.69% 406.30%
Operating Expenses to Revenue
171.46% 464.66% 496.26% 576.01% 301.41% 490.52%
Earnings before Interest and Taxes (EBIT)
-22 -65 -118 -184 -155 -213
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-20 -63 -110 -173 -147 -208
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 5.71 3.76 1.92 1.50 2.97
Price to Tangible Book Value (P/TBV)
0.00 5.71 3.76 1.92 1.50 2.97
Price to Revenue (P/Rev)
6.72 92.93 43.22 15.12 3.92 28.71
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
7.04 72.05 28.67 5.47 0.08 17.54
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
364.34 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
4.02 -1.43 -1.26 -1.25 -1.33 -1.24
Leverage Ratio
-4.63 1.57 1.38 1.38 1.53 1.41
Compound Leverage Factor
-4.47 1.54 1.37 1.36 1.42 1.28
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-506.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
606.30% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.09 9.27 4.95 1.10 -1.50 5.03
Noncontrolling Interest Sharing Ratio
-506.30% 17.17% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
2.44 6.70 4.70 4.51 3.40 6.46
Quick Ratio
2.34 6.31 4.55 4.38 3.31 6.36
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -20 -65 -150 -83 -161
Operating Cash Flow to CapEx
36.40% -1.76% -1,490.28% -1,305.19% -968.52% -1,861.15%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.71 0.08 0.07 0.09 0.20 0.11
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
8.04 3.38 3.30 2.71 4.53 3.16
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-48 -73 -91 -69 -95 -83
Invested Capital Turnover
-0.65 -0.29 -0.36 -0.48 -0.94 -0.61
Increase / (Decrease) in Invested Capital
0.00 -26 -17 21 -26 12
Enterprise Value (EV)
219 1,284 853 211 6.36 957
Market Capitalization
209 1,656 1,286 584 302 1,566
Book Value per Share
($17.53) $7.47 $7.67 $6.44 $4.13 $7.44
Tangible Book Value per Share
($17.53) $7.47 $7.67 $6.44 $4.13 $7.44
Total Capital
-9.52 290 342 304 200 527
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-38 -372 -433 -373 -295 -610
Capital Expenditures (CapEx)
1.65 4.55 5.66 12 8.40 9.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-15 -27 -51 -61 -79 -86
Debt-free Net Working Capital (DFNWC)
23 254 245 248 209 524
Net Working Capital (NWC)
23 254 245 248 209 524
Net Nonoperating Expense (NNE)
6.13 -2.25 35 52 35 44
Net Nonoperating Obligations (NNO)
-38 -364 -433 -373 -295 -610
Total Depreciation and Amortization (D&A)
2.25 2.45 7.79 11 8.23 5.14
Debt-free, Cash-free Net Working Capital to Revenue
-46.61% -152.93% -170.96% -158.82% -103.09% -157.75%
Debt-free Net Working Capital to Revenue
74.62% 1,424.78% 823.06% 641.50% 270.88% 959.75%
Net Working Capital to Revenue
74.62% 1,424.78% 823.06% 641.50% 270.88% 959.75%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($2.76) ($2.73) ($3.71) ($2.65) ($2.88)
Adjusted Weighted Average Basic Shares Outstanding
0.00 38.91M 44.74M 48.61M 54.34M 67.12M
Adjusted Diluted Earnings per Share
$0.00 ($2.76) ($2.73) ($3.71) ($2.65) ($2.88)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 38.91M 44.74M 48.61M 54.34M 67.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($2.76) ($2.73) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 15.67M 42.90M 47.27M 48.89M 75.89M
Normalized Net Operating Profit after Tax (NOPAT)
-16 -45 -83 -129 -109 -149
Normalized NOPAT Margin
-50.02% -255.26% -277.38% -333.20% -140.99% -273.37%
Pre Tax Income Margin
-68.97% -357.90% -393.49% -466.93% -186.98% -354.36%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Nurix Therapeutics

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 11/30/2022 2/28/2023 5/31/2023 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025 5/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-8.29% 31.85% 168.33% 71.13% 123.49% 30.75% -60.58% -31.84% -12.37% 11.26% 264.34%
EBITDA Growth
-29.57% -1.60% 42.71% 12.52% 5.96% -6.58% -90.84% -41.54% -46.62% -43.99% 1.46%
EBIT Growth
-28.29% -0.49% 41.45% 14.35% 6.89% -5.28% -81.36% -36.49% -42.62% -39.02% 0.45%
NOPAT Growth
-28.29% -0.49% 41.45% 14.35% 6.89% -5.28% -81.36% -36.49% -42.62% -39.02% 0.45%
Net Income Growth
-23.91% 4.23% 46.53% 19.09% 10.19% -1.93% -83.49% -32.38% -39.55% -35.73% 2.43%
EPS Growth
0.00% 21.05% 55.45% 24.44% 9.41% -1.33% -57.78% 1.47% 3.90% 11.84% 26.76%
Operating Cash Flow Growth
-22.79% -13.66% 43.89% 11.18% 170.32% 13.42% -114.98% -2.54% -282.66% -45.62% -59.08%
Free Cash Flow Firm Growth
-488.93% 3.38% -8.07% -23.83% 88.76% 104.02% 98.33% 111.73% -824.26% -2,696.61% -8,794.76%
Invested Capital Growth
23.49% 35.37% 40.64% 50.86% -36.80% -65.95% -67.96% -131.03% 12.91% 19.61% 53.34%
Revenue Q/Q Growth
-37.14% 87.01% 141.83% -39.80% -17.91% 9.41% -27.09% 4.10% 5.53% 38.91% 138.75%
EBITDA Q/Q Growth
-5.84% 12.34% 39.83% -56.72% -13.77% 0.65% -7.74% -16.23% -17.86% 2.43% 26.27%
EBIT Q/Q Growth
-4.22% 11.78% 37.69% -49.49% -13.30% 0.25% -7.34% -12.51% -18.40% 2.77% 23.13%
NOPAT Q/Q Growth
-4.22% 11.78% 37.69% -49.49% -13.30% 0.25% -7.34% -12.51% -18.40% 2.77% 23.13%
Net Income Q/Q Growth
-2.21% 12.81% 40.40% -52.33% -13.45% 1.04% -7.29% -9.90% -19.60% 3.75% 22.87%
EPS Q/Q Growth
5.56% 11.76% 40.00% -51.11% -13.24% 1.30% 6.58% 5.63% -10.45% 9.46% 22.39%
Operating Cash Flow Q/Q Growth
18.04% -27.66% 61.88% -122.71% 164.88% -257.18% 5.35% -6.23% -15.59% -25.30% -3.40%
Free Cash Flow Firm Q/Q Growth
-6.87% -5.24% 10.60% -23.14% 90.30% 137.62% -137.21% 963.75% -864.37% -5.69% -27.47%
Invested Capital Q/Q Growth
2.44% 25.65% 5.48% 28.33% -171.60% 9.81% 4.34% 1.42% -2.38% 16.74% 44.48%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-682.63% -319.98% -79.61% -207.25% -287.26% -260.84% -385.44% -430.34% -480.63% -337.58% -104.24%
Operating Margin
-717.82% -338.60% -87.25% -216.67% -299.06% -272.65% -401.42% -433.83% -486.73% -340.67% -109.68%
EBIT Margin
-717.82% -338.60% -87.25% -216.67% -299.06% -272.65% -401.42% -433.83% -486.73% -340.67% -109.68%
Profit (Net Income) Margin
-688.74% -321.11% -79.14% -200.26% -276.77% -250.33% -368.39% -388.91% -440.75% -305.38% -98.66%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.22% 100.20% 100.17% 100.01% 100.00% 101.78%
Interest Burden Percent
95.95% 94.83% 90.70% 92.43% 92.55% 91.62% 91.59% 89.49% 90.54% 89.64% 88.37%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-55.84% -61.58% -59.79% -51.60% -57.10% -65.37% -52.33% -57.96% -53.22% -64.16% -50.67%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-62.06% -34.95% -14.27% -38.74% -59.62% -64.60% -58.05% -59.57% -51.81% -41.43% -17.58%
Return on Assets (ROA)
-59.55% -33.14% -12.95% -35.80% -55.18% -59.31% -53.27% -53.40% -46.91% -37.14% -15.82%
Return on Common Equity (ROCE)
-55.84% -61.58% -59.79% -51.60% -57.10% -65.37% -52.33% -57.96% -53.22% -64.16% -50.67%
Return on Equity Simple (ROE_SIMPLE)
0.00% -65.16% -60.57% -63.60% 0.00% -85.77% -44.51% -46.96% 0.00% -43.33% -46.32%
Net Operating Profit after Tax (NOPAT)
-34 -30 -19 -28 -32 -32 -34 -38 -45 -44 -34
NOPAT Margin
-502.48% -237.02% -61.08% -151.67% -209.34% -190.86% -281.00% -303.68% -340.71% -238.47% -76.78%
Net Nonoperating Expense Percent (NNEP)
-3.14% -3.00% -1.69% -2.63% -3.06% -3.40% -2.78% -2.95% -2.94% -3.07% -2.05%
Return On Investment Capital (ROIC_SIMPLE)
-11.22% - - - -15.83% - - - -8.59% -9.15% -7.56%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
138.10% 77.42% 38.07% 57.52% 71.11% 71.14% 96.84% 93.09% 80.68% 63.16% 32.42%
R&D to Revenue
679.73% 361.18% 149.18% 259.14% 327.94% 301.51% 404.58% 440.75% 506.05% 377.52% 177.27%
Operating Expenses to Revenue
817.82% 438.60% 187.25% 316.67% 399.06% 372.65% 501.42% 533.83% 586.73% 440.67% 209.68%
Earnings before Interest and Taxes (EBIT)
-49 -43 -27 -40 -45 -45 -49 -55 -65 -63 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-46 -41 -24 -38 -44 -43 -47 -54 -64 -62 -46
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.92 1.63 1.85 1.75 1.50 3.55 2.09 4.31 2.97 2.44 1.81
Price to Tangible Book Value (P/TBV)
1.92 1.63 1.85 1.75 1.50 3.55 2.09 4.31 2.97 2.44 1.81
Price to Revenue (P/Rev)
15.12 10.69 7.88 5.97 3.92 7.41 12.43 28.77 28.71 20.78 9.17
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
5.47 2.88 2.81 2.05 0.08 4.26 5.16 20.66 17.54 11.04 3.67
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.25 -1.23 -1.25 -1.18 -1.33 -1.31 -1.21 -1.19 -1.24 -1.24 -1.15
Leverage Ratio
1.38 1.39 1.41 1.33 1.53 1.54 1.37 1.35 1.41 1.43 1.35
Compound Leverage Factor
1.33 1.32 1.28 1.23 1.42 1.41 1.25 1.20 1.28 1.28 1.19
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
2.17 1.57 1.98 1.62 -0.48 0.28 2.26 5.89 5.76 4.11 2.16
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.51 4.44 4.01 4.36 3.40 2.86 5.57 5.28 6.46 6.26 6.82
Quick Ratio
4.38 4.27 3.89 4.24 3.31 2.78 5.49 5.19 6.36 6.11 6.68
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-55 -58 -52 -64 -6.22 2.34 -0.87 7.52 -58 -61 -77
Operating Cash Flow to CapEx
-1,479.73% -2,127.89% -1,710.09% -1,672.75% 1,032.46% -1,454.61% -2,049.82% -1,797.06% -2,315.96% -1,752.86% -2,361.16%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.09 0.10 0.16 0.18 0.20 0.24 0.14 0.14 0.11 0.12 0.16
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
2.71 2.67 3.58 4.15 4.53 4.55 3.36 3.35 3.16 3.11 4.74
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-69 -52 -49 -35 -95 -86 -82 -81 -83 -69 -38
Invested Capital Turnover
-0.48 -0.64 -0.93 -1.29 -0.94 -1.18 -0.95 -0.98 -0.61 -0.73 -1.47
Increase / (Decrease) in Invested Capital
21 28 33 36 -26 -34 -33 -46 12 17 44
Enterprise Value (EV)
211 120 172 141 6.36 345 322 1,166 957 623 325
Market Capitalization
584 446 480 410 302 599 774 1,623 1,566 1,172 810
Book Value per Share
$6.44 $5.80 $5.48 $4.85 $4.13 $3.07 $7.54 $5.85 $7.44 $6.34 $5.87
Tangible Book Value per Share
$6.44 $5.80 $5.48 $4.85 $4.13 $3.07 $7.54 $5.85 $7.44 $6.34 $5.87
Total Capital
304 274 260 234 200 169 371 377 527 481 448
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-373 -326 -309 -269 -295 -254 -453 -458 -610 -550 -486
Capital Expenditures (CapEx)
2.57 2.28 1.08 2.46 2.59 2.88 1.94 2.35 2.11 3.49 2.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-61 -54 -63 -52 -79 -81 -74 -78 -86 -76 -46
Debt-free Net Working Capital (DFNWC)
248 223 218 206 209 163 369 370 524 474 440
Net Working Capital (NWC)
248 223 218 206 209 163 369 370 524 474 440
Net Nonoperating Expense (NNE)
13 11 5.54 8.97 10 9.86 11 11 13 12 9.64
Net Nonoperating Obligations (NNO)
-373 -326 -309 -269 -295 -254 -453 -458 -610 -550 -486
Total Depreciation and Amortization (D&A)
2.39 2.36 2.34 1.74 1.79 1.96 1.93 0.44 0.81 0.57 2.40
Debt-free, Cash-free Net Working Capital to Revenue
-158.82% -128.79% -104.09% -76.37% -103.09% -99.70% -118.29% -138.78% -157.75% -134.65% -52.12%
Debt-free Net Working Capital to Revenue
641.50% 535.97% 357.35% 300.91% 270.88% 201.94% 592.97% 655.30% 959.75% 839.67% 497.52%
Net Working Capital to Revenue
641.50% 535.97% 357.35% 300.91% 270.88% 201.94% 592.97% 655.30% 959.75% 839.67% 497.52%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.85) ($0.75) ($0.45) ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding
48.61M 54.03M 54.26M 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M
Adjusted Diluted Earnings per Share
($0.85) ($0.75) ($0.45) ($0.68) ($0.77) ($0.76) ($0.71) ($0.67) ($0.74) ($0.67) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding
48.61M 54.03M 54.26M 54.39M 54.34M 54.90M 62.38M 72.78M 67.12M 83.56M 83.88M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
47.27M 47.45M 48.20M 48.50M 48.89M 49.15M 64.41M 70.84M 75.89M 76.24M 76.45M
Normalized Net Operating Profit after Tax (NOPAT)
-34 -30 -19 -28 -32 -32 -34 -38 -45 -44 -34
Normalized NOPAT Margin
-502.48% -237.02% -61.08% -151.67% -209.34% -190.86% -281.00% -303.68% -340.71% -238.47% -76.78%
Pre Tax Income Margin
-688.74% -321.11% -79.14% -200.26% -276.77% -249.79% -367.65% -388.26% -440.69% -305.38% -96.93%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Nurix Therapeutics (NASDAQ: NRIX) continues to operate in a challenging environment as a biotechnology company, with consistent net losses reported over the past several quarters and years. Here is an analysis of key financial trends based on the last four years of quarterly data, focusing on the latest available quarter Q2 2025 and comparing it with earlier periods.

  • In Q2 2025, Nurix generated $44.1 million in operating revenue, showing strong growth compared to prior quarters such as Q1 2025 ($18.5 million) and significantly higher than 2024 quarters (around $12M to $18M range).
  • Cash and short-term investments totaled $485.8 million at the end of Q2 2025, providing a solid liquidity position to fund ongoing research and development activities.
  • Interest and investment income contributed $5.6 million in Q2 2025, partially offsetting operating losses and indicating good return on investment assets.
  • The weighted average shares outstanding increased over time to approximately 83.8 million shares in Q2 2025 from around 54 million in early 2023, which may dilute EPS but supports capital raising efforts.
  • Nurix reported a net loss of $43.5 million in Q2 2025, continuing a persistent trend of losses each quarter since at least 2022, reflecting heavy investment in R&D.
  • Research & Development expenses remain very high at $78.1 million in Q2 2025, an increase from prior quarters, pressuring profitability but critical to the company's pipeline development.
  • Selling, General & Administrative expenses also increased to $14.3 million in Q2 2025, indicating rising operating costs as the company scales.
  • Net cash used in operating activities was substantial at $63.2 million in Q2 2025, up from $61.1 million in Q1 2025, showing continued cash burn.
  • Total operating expenses of $92.4 million in Q2 2025 significantly exceeded revenues, resulting in an operating loss of $48.3 million.
  • Despite losses, the company is investing in property, plant, and equipment and continues to actively manage its investment portfolio, seen by purchases and sales of investments contributing strongly to positive net cash from investing activities ($71.5 million) in Q2 2025.

Summary: Nurix Therapeutics has demonstrated revenue growth and maintains strong liquidity backed by significant cash, investments, and capital raises. However, the company remains unprofitable with consistently high R&D and operating expenses leading to ongoing net losses and negative operating cash flow. Investors should recognize Nurix's profile as a development-stage biotech company investing heavily for future growth, with profitability still a longer-term prospect.

08/08/25 06:04 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Nurix Therapeutics' Financials

When does Nurix Therapeutics' financial year end?

According to the most recent income statement we have on file, Nurix Therapeutics' fiscal year ends in November. Their fiscal year 2024 ended on November 30, 2024.

How has Nurix Therapeutics' net income changed over the last 5 years?

Nurix Therapeutics' net income appears to be on an upward trend, with a most recent value of -$193.57 million in 2024, rising from -$21.70 million in 2019. The previous period was -$143.95 million in 2023. See where experts think Nurix Therapeutics is headed by visiting Nurix Therapeutics' forecast page.

What is Nurix Therapeutics' operating income?
Nurix Therapeutics' total operating income in 2024 was -$213.03 million, based on the following breakdown:
  • Total Gross Profit: $54.55 million
  • Total Operating Expenses: $267.58 million
How has Nurix Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Nurix Therapeutics' total revenue changed from $31.12 million in 2019 to $54.55 million in 2024, a change of 75.3%.

How much debt does Nurix Therapeutics have?

Nurix Therapeutics' total liabilities were at $142.35 million at the end of 2024, a 8.2% decrease from 2023, and a 165.7% increase since 2019.

How much cash does Nurix Therapeutics have?

In the past 5 years, Nurix Therapeutics' cash and equivalents has ranged from $34.82 million in 2019 to $119.36 million in 2020, and is currently $110.00 million as of their latest financial filing in 2024.

How has Nurix Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Nurix Therapeutics' book value per share changed from -17.53 in 2019 to 7.44 in 2024, a change of -142.4%.



This page (NASDAQ:NRIX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners